REFERENCES:
1. Cooper GM. The Development and Causes of Cancer. Cell Mol Approach 2nd Ed [Internet]. 2000 [cited 2019 Aug 23]; Available from: https://www.ncbi.nlm.nih.gov/books/NBK9963/
2. Lassere MN. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat Methods Med Res. 2008 Jun;17(3):303–40.
3. Goossens N, Nakagawa S, Sun X, Hoshida Y. Cancer biomarker discovery and validation. Transl Cancer Res. 2015 Jun;4(3):256–69.
4. Haggar FA, Boushey RP. Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors. Clin Colon Rectal Surg. 2009 Nov;22(4):191–7.
5. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. N Engl J Med. 2003 Jul 17;349(3):247–57.
6. Krämer I, Lipp H-P. Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. J Clin Pharm Ther. 2007;32(1):1–14.
7. Xiang B, Snook AE, Magee MS, Waldman SA. Colorectal Cancer Immunotherapy. Discov Med. 2013 May;15(84):301–8.
8. Morita R, Hirohashi Y, Torigoe T, Ito-Inoda S, Takahashi A, Mariya T, et al. Olfactory Receptor Family 7 Subfamily C Member 1 Is a Novel Marker of Colon Cancer–Initiating Cells and Is a Potent Target of Immunotherapy. Clin Cancer Res. 2016 Jul 1;22(13):3298–309.
9. Guéguinou M, Harnois T, Crottes D, Uguen A, Deliot N, Gambade A, et al. SK3/TRPC1/Orai1 complex regulates SOCE-dependent colon cancer cell migration: a novel opportunity to modulate anti-EGFR mAb action by the alkyl-lipid Ohmline. Oncotarget. 2016 Apr 18;7(24):36168–84.
10. Rupp C, Scherzer M, Rudisch A, Unger C, Haslinger C, Schweifer N, et al. IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor–stroma interaction. Oncogene. 2015 Feb;34(7):815–25.
11. Yun Q, Wong CC, Yu J. IDDF2019-ABS-0203 SCNN1B Functions as a tumor suppressor in colorectal cancer by inhibiting RAS-RAF-MEK-ERK pathway. Gut. 2019 Jun 1;68(Suppl 1):A20–A20.
12. Wan L, Yu W, Shen E, Sun W, Liu Y, Kong J, et al. SRSF6-regulated alternative splicing that promotes tumour progression offers a therapy target for colorectal cancer. Gut. 2019 Jan 1;68(1):118–29.
13. Wang H-Y, Long Q-Y, Tang S-B, Xiao Q, Gao C, Zhao Q-Y, et al. Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic Acids Res. 2019 Mar 18;47(5):2349–64.
14. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
15. Kanwal M, Ding X-J, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017 Feb;13(2):535–42.
16. Tang D, Shen Y, Wang M, Yang R, Wang Z, Sui A, et al. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. Eur J Cancer Prev. 2013 Nov;22(6):540.
17. Kohno T, Tsuta K, Tsuchihara K, Nakaoku T, Yoh K, Goto K. RET fusion gene: Translation to personalized lung cancer therapy [Internet]. Cancer Science. 2013 [cited 2019 Aug 5]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/cas.12275
18. Antonia S, Goldberg SB, Balmanoukian A, Chaft JE, Sanborn RE, Gupta A, et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. Lancet Oncol. 2016 Mar 1;17(3):299–308.
19. Muralidharan R, Panneerselvam J, Chen A, Zhao YD, Munshi A, Ramesh R. HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer. Cancer Gene Ther. 2015 Dec;22(12):581–90.
20. La‐Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy [Internet]. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2015 [cited 2019 Aug 5]. Available from: https://accpjournals.onlinelibrary.wiley.com/ doi/abs/10.1002/phar.1643
21. Caiola E, Falcetta F, Giordano S, Marabese M, Garassino MC, Broggini M, et al. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach. J Exp Clin Cancer Res. 2018 Dec 4;37(1):302.
22. Sironi J, Aranda E, Nordstrøm LU, Schwartz EL. Lysosome Membrane Permeabilization and Disruption of the Molecular Target of Rapamycin (mTOR)-Lysosome Interaction Are Associated with the Inhibition of Lung Cancer Cell Proliferation by a Chloroquinoline Analog. Mol Pharmacol. 2019 Jan 1;95(1):127–38.
23. Otsuki Y, Saya H, Arima Y. Prospects for new lung cancer treatments that target EMT signaling. Dev Dyn. 2018;247(3):462–72.
24. U.S. Breast Cancer Statistics [Internet]. Breastcancer.org. 2019 [cited 2019 Aug 6]. Available from: https://www.breastcancer.org/ symptoms/understand_bc/statistics
25. Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Przegla̜d Menopauzalny Menopause Rev. 2015 Sep;14(3):196–202.
26. Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) | Cancer Research [Internet]. [cited 2019 Aug 8]. Available from: https://cancerres.aacrjournals.org/content/ 75/15_Supplement/2859.short#
27. JCI - TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer [Internet]. [cited 2019 Aug 8]. Available from: https://www.jci.org/articles/view/65416
28. PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer | Cancer Immunology Research [Internet]. [cited 2019 Aug 8]. Available from: https:// cancerimmunolres. aacrjournals.org/content/3/4/326?utm_source=rimm&utm_medium=bestofauthorpage&utm_campaign=140133
29. Elbaz M, Ahirwar D, Xiaoli Z, Zhou X, Lustberg M, Nasser MW, et al. TRPV2 is a novel biomarker and therapeutic target in triple negative breast cancer. Oncotarget. 2016 May 27;9(71):33459–70.
30. Geffken K, Spiegel S. Sphingosine kinase 1 in breast cancer. Adv Biol Regul. 2018 Jan 1; 67:59–65.
31. Lee M-H, Koh D, Na H, Ka N-L, Kim S, Kim H-J, et al. MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. Autophagy. 2018 May 4;14(5):812–24.
32. Petruzziello A. Epidemiology of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Related Hepatocellular Carcinoma. Open Virol J. 2018 Feb 28; 12:26–32.
33. Janevska D, Chaloska-Ivanova V, Janevski V. Hepatocellular Carcinoma: Risk Factors, Diagnosis and Treatment. Open Access Maced J Med Sci. 2015 Dec 15;3(4):732–6.
34. Hien DT, Takai A, Forgues M, Wang XW. Abstract 1985: Oncogenic activation of RNA binding proteins and c-Myc signaling in hepatocellular carcinoma. Cancer Res. 2016 Jul 15;76(14 Supplement):1985–1985.
35. Lin Y-Y, Tan C-T, Chen C-W, Ou D-L, Cheng A-L, Hsu C. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy. Semin Liver Dis. 2018 Nov;38(4):379–88.
36. Dietrich P, Gaza A, Wormser L, Fritz V, Hellerbrand C, Bosserhoff AK. Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Is a Novel Prognostic Marker and Contributes to Sorafenib Resistance in Hepatocellular Carcinoma. Neoplasia. 2019 Mar 1;21(3):257–68.
37. Zahid KR, Han S, Zhou F, Raza U. Novel tumor suppressor SPRYD4 inhibits tumor progression in hepatocellular carcinoma by inducing apoptotic cell death. Cell Oncol. 2019 Feb 1;42(1):55–66.
38. Tsuge S, Saberi B, Cheng Y, Wang Z, Kim A, Luu H, et al. Detection of Novel Fusion Transcript VTI1A-CFAP46 in Hepatocellular Carcinoma. Gastrointest Tumors. 2019;6(1–2):11–27.